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Abstract
Background Abdominal aortic calcification (AAC) is
independently associated with cardiovascular events in
dialysis patients and in the general population. However,
data in non-dialysis chronic kidney disease (CKD) patients
are limited. We analyzed determinants and prognostic
value of AAC in non-dialysis CKD patients.
Methods We included patients with CKD not receiving
renal replacement therapy from the MASTERPLAN study,
a randomized controlled trial that started in 2004. In the
period 2008–2009, an X-ray to evaluate AAC was per-
formed in a subgroup of patients. We studied AAC using a
semi-quantitative scoring system by lateral lumbar X-ray.
We used baseline and 2-year data to find determinants of
AAC. We used a composite cardiovascular endpoint and
propensity score matching to evaluate the prognostic value
of AAC.
Results In 280 patients an X-ray was performed. In 79
patients (28 %) the X-ray showed no calcification, in 62
patients (22 %) calcification was minor (\4), while 139
patients (50 %) had moderate or heavy calcification (C4).
Older age, prior cardiovascular disease, higher triglyceride
levels, and higher phosphate levels were independent
determinants of a calcification score C4. AAC score C4
was independently associated with cardiovascular events,
with a hazard ratio of 5.5 (95 % confidence interval
1.2–24.8).
Conclusions Assessment of AAC can identify CKD
patients at higher cardiovascular risk, and may provide
important information for personalized treatment. Whether
this approach will ultimately translate into better outcomes
remains to be answered.
Keywords Abdominal aortic calcification 
Cardiovascular risk  Chronic kidney disease  Prognosis
Introduction
Patients with chronic kidney disease (CKD) are at
increased risk of cardiovascular events [1]. Disturbances in
bone and mineral metabolism play an important role. For
example, hyperparathyroidism, hypercalcemia, hyper-
phosphatemia, and elevated fibroblast growth factor 23
(FGF23) are associated with cardiovascular morbidity and
mortality [2, 3]. It has been suggested that disturbances in
bone and mineral metabolism cause vascular calcification
[4, 5]. Vascular calcification, either in the coronary arteries
or in the aorta, is related to cardiovascular events in dial-
ysis patients and in the general population [6–10]. The
2009 Kidney Disease: Improving Global Outcomes
(KDIGO) clinical practice guideline on CKD mineral and
bone disorder (CKD-MBD) suggests using plain radio-
graphs to evaluate abdominal aortic calcification (AAC) in
selected patients in order to assist in personalized treatment
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advice [11]. However, data on the prognostic value of AAC
in non-dialysis CKD patients are limited [12, 13]. There-
fore, we studied the severity, determinants, and prognostic
value of AAC in non-dialysis CKD patients.
Methods
Design and patient selection
The MASTERPLAN (Multifactorial Approach and Supe-
rior Treatment Efficacy in Renal Patients with the Aid of
Nurse practitioners) study was a randomized controlled
trial that evaluated the added value of nurse practitioner
care in reducing cardiovascular events and attenuating
kidney function decline in patients with prevalent CKD
[ISRCTN registry number 73187232]. Its rationale, design
and outcomes have been published elsewhere [14–16].
Ethics committee approval was obtained for the study as
well as written informed consent from all participants.
Patients were included in the study between April 2004 and
December 2005, and followed thereafter. Although specific
treatment goals were defined, routine patient care was left
to the discretion of the treating practitioner. In the period
2008–2009 nephrologists considered the role of evaluating
AAC in selected patients, based on the data and discussions
that resulted in the recommendation in the 2009 KDIGO
CKD-MBD guideline [11]. The MASTERPLAN steering
committee at that time decided that performing a lateral
lumbar X-ray was not part of the study protocol, but the
decision whether to use it in patient care was left to the
treating nephrologist.
We evaluated the use of the lateral lumbar X-ray in
CKD patients that participated in the MASTERPLAN
study. We included non-transplanted patients with a lateral
lumbar X-ray in 2008–2009 who did not develop end-stage
renal disease (ESRD) before the X-ray was taken. For
comparison, we also selected all non-transplanted patients
without an X-ray in 2008–2009 who did not develop ESRD
before 2008.
Assessment of AAC
We reviewed all lateral lumbar X-rays. For evaluation of
AAC, we used a semi-quantitative scoring system, as
described by Kauppila et al. [17]. Briefly, the abdominal
aorta adjacent to the first four lumbar vertebrae was divided
into four segments using the midpoint of each interverte-
bral space as a boundary. Anterior and posterior aortic wall
segments were evaluated separately. Calcific deposits were
graded on a scale of 0–3 at each segment, as follows:
0 = no calcific deposits, 1 = small scattered calcific
deposits filling less than one-third of the aortic wall,
2 = one-third to two-thirds of the aortic wall calcified,
3 = at least two-thirds of the aortic wall calcified. The
grades of the eight aortic segments were summed in the
Kauppila calcification score (the antero-posterior severity
score), ranging from 0 to 24 points. Two independent
observers (MP and YK) scored all lateral lumbar X-rays.
Both observers were blinded to the clinical and laboratory
patient data.
Cardiovascular outcome
As described before, follow-up in the MASTERPLAN
study was extended for the analysis of renal endpoints [16].
We retrieved information on mortality and renal outcome
parameters from the participating centers. At the same
time, we collected additional data on cardiovascular events.
In this study we used a composite cardiovascular outcome
of myocardial infarction, coronary artery bypass grafting,
percutaneous coronary intervention (PCI), stroke, percuta-
neous treatment of peripheral arterial disease (PTA),
bypass of peripheral arteries, amputation, treatment of
aortic aneurysm, treatment of renal artery stenosis, and
cardiovascular mortality.
Statistical analyses
We compared baseline characteristics of patients with an
X-ray vs. patients without an X-ray using independent-
samples T test, Mann–Whitney U test, and Chi square test
where appropriate. We calculated the linearly weighted
Kappa to evaluate inter-rater agreement [18]. We used the
mean scores attributed by the two observers in the subse-
quent analyses.
For continuous variables, we used mean values of
MASTERPLAN baseline characteristics and those at
2 years to represent the period before the lateral lumbar
X-ray. We considered a categorical variable present when
it was present either at baseline or at 2 years. We imputed
missing data by multiple imputation before mean values
were computed [19]. Fifty imputed datasets were created.
At baseline, data for nine variables were missing with
missing percentages of 0.4–10.4 % per variable. At 2-year
follow-up, almost all variables had missing data with
missing percentages of 1.8–18.2 % per variable.
We tabulated patient characteristics, expressed as a
percentage for categorical, and mean ± standard deviation
(SD), or median and interquartile range (IQR) for contin-
uous variables, by low (\4, no or minor calcification) vs.
high calcification score (C4, moderate or heavy calcifica-
tion). Differences between the groups were studied by
logistic regression. On the basis of our previous analyses,
we expected a low cardiovascular event rate [15]. Since the
study population for the current analyses was quite small,
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we chose to primarily dichotomize AAC into groups of
equal size. This decision also seemed reasonable, given
that other investigators have also divided their population
on the basis of median AAC [20, 21].
Next, we used multivariate logistic regression to identify
independent determinants of AAC.
We performed Cox regression to analyze univariate
relationships between patient characteristics and cardio-
vascular events. Because of the low incidence of cardio-
vascular events, and therefore the limited number of
predictors that could be included in multivariate Cox
regression analysis, we used propensity score matching to
determine whether AAC may add prognostic value beyond
known predictive factors for cardiovascular events [22, 23].
Using a multivariate logistic regression model including
known predictors of cardiovascular events, we estimated the
probability of a high calcification score (C4). This is the
propensity score. Among patients with a similar propensity
score, some in actual fact have a high and others a low cal-
cification score. Matching two patients with similar
propensity scores (one with a high and one with a low cal-
cification score) yields pairs of patients who are comparable
in terms of cardiovascular risk factors, except for the calci-
fication score. If a difference in cardiovascular outcome is
subsequently observed, it indicates that AAC has prognostic
value over and above the traditional risk factors.
We included the following clinical risk factors (mainly
on the basis of the Framingham Risk Score [24]) in the
multivariate logistic regression model: age, gender, history
of diabetes mellitus, prior cardiovascular disease, systolic
blood pressure, low-density lipoprotein (LDL) cholesterol,
high-density lipoprotein (HDL) cholesterol, smoking sta-
tus, antihypertensive drug use, triglyceride and phosphate
levels. Propensity scores were estimated for all imputed
datasets, the average for every patient was used for
propensity score matching [25]. A caliper distance of 0.01
was used. In this matched sample, we performed Kaplan–
Meier analysis and Cox regression stratified on the mat-
ched pairs.
We performed two sensitivity analyses. First, we evalu-
ated absence versus presence of calcification in addition to
the analyses comparing patients with low and high calcifi-
cation score. Second, to evaluate the influence of AAC on
therapeutic decision making, we compared mean clinical
parameters and medication use of the two visits after the
X-ray to characteristics in the period before the X-ray was
taken.
All p-values were two-sided, and a p\ 0.05 was con-
sidered to indicate statistical significance. Analyses were
performed using IBM SPSS Statistics Version 20 (IBM
Corporation, Armonk, NY, USA). Cox regression stratified
on matched pairs was performed using Stata 11.2 (Stata-
Corp LP, College Station, TX, USA).
Results
We evaluated lateral lumbar X-rays taken in the period
2008–2009. In 7 out of 9 centers participating in MASTER-
PLAN, X-rays were performed. The percentage of patients
with an X-ray ranged from 26 to 65 % per center. In total, we
included in this study 280 patients with available lateral
lumbar X-rays. For comparison purposes, we used data of
patients without an X-ray who were followed in the 7 centers.
The patients with an X-ray were randomized to the inter-
vention group, adhered to the physical activity guideline, and
used aspirin more often than patients without an X-ray. Fur-
thermore, patients with an X-ray had a higher ankle brachial
index, lower protein creatinine ratio, higher HDL cholesterol,
lower phosphate, and lower FGF23 levels (Supplementary
Table 1). The lateral lumbar X-rays were taken within a
median of 3.7 years [IQR 3.1–4.0] of baseline.
Assessment and severity of AAC
Inter-rater agreement was very good with a linearly weighted
Kappa of 0.87 (Supplementary Data 1) [18]. Supplementary
Fig. 1 shows the frequencies of calcification scores attributed
by the two observers. The frequency distribution, using the
mean scores of the two observers, is illustrated in Fig. 1. The
median calcification score was 3.5 [IQR 0–8.9]. In 79 patients
(28 %) the X-ray showed no AAC. Calcification was more
prominent in the lower segments of the aorta. Furthermore,
calcification scores were higher in the posterior wall com-
pared to the anterior wall (Supplementary Fig. 2).
Determinants of AAC
Table 1 shows characteristics of patients with a low calcifi-
cation score (\4) compared to patients with a high calcifi-
cation score (C4). The patients who had a higher calcification
Fig. 1 Severity of abdominal aortic calcification (X-rays, n = 280).
The median calcification score was 3.5, interquartile range 0–8.9
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score were older, more often had a history of diabetes mellitus
(and higher HbA1c levels) and cardiovascular disease. Fur-
thermore, a higher calcification score was associated with
higher systolic blood pressure, triglyceride and phosphate
levels, and lower ankle brachial index. Patients with a high
calcification score used a statin and antihypertensive drugs
more often than patients with a low calcification score. Esti-
mated glomerular filtration rate (eGFR) did not differ between
Table 1 Characteristics of
patients by calcification score
Characteristic Calcification score p
\4 (n = 141) C4 (n = 139)
Randomized to intervention group 61 % 56 % 0.41
Age (years) 55.2 (12.9) 65.9 (8.3) \0.001
Male gender 67 % 70 % 0.66
Caucasian race 89 % 90 % 0.88
Renovascular cause of kidney disease 28 % 35 % 0.22
History of diabetes mellitusa 20 % 33 % 0.01
Prior cardiovascular diseaseb 18 % 42 % \0.001
eGFRc (ml/min/1.73 m2) 36.6 (12.0) 36.3 (13.3) 0.81
Systolic blood pressure (mmHg) 132 (15) 138 (18) 0.004
Diastolic blood pressure (mmHg) 80 (10) 78 (10) 0.12
Ankle brachial indexd 1.12 (0.17) 1.07 (0.20) 0.01
Protein creatinine ratio (mg/10 mmol) 123 [27–472] 121 [18–646] 0.17
Total cholesterol (mmol/l) 4.64 (0.85) 4.63 (0.82) 0.92
LDL cholesterol (mmol/l) 2.61 (0.81) 2.56 (0.70) 0.56
HDL cholesterol (mmol/l) 1.39 (0.42) 1.31 (0.39) 0.10
Triglycerides (mmol/l) 1.56 (0.83) 1.81 (0.98) 0.03
Calcium (mmol/l) 2.36 (0.11) 2.36 (0.12) 0.74
Phosphate (mmol/l) 1.07 (0.19) 1.14 (0.20) 0.003
PTH (pmol/l) 7.5 [5.6–11.8] 8.3 [5.5–12.0] 0.66
FGF23 (RU/ml) 99 [63–161] 134 [70–191] 0.14
Hemoglobin (mmol/l) 8.4 (0.9) 8.3 (0.8) 0.55
Serum albumin (g/l) 40.5 (3.4) 39.7 (3.1) 0.04
HbA1c (%) 5.9 (0.8) 6.2 (0.7) \0.001
BMI (kg/m2) 26.2 (4.8) 27.1 (3.8) 0.09
Smoking 22 % 21 % 0.85
Urinary sodium creatinine ratio (mmol/mmol) 13.9 (4.6) 14.1 (4.8) 0.72
Physical activity guideline adherence 79 % 78 % 0.82
Aspirin use 57 % 64 % 0.22
Oral anticoagulant drug use 11 % 15 % 0.33
Statin use 87 % 95 % 0.02
Vitamin D use 41 % 42 % 0.87
Antihypertensive drug use 93 % 99 % 0.04
Calcium containing phosphate binder use 12 % 10 % 0.50
Sevelamer use 6 % 6 % 0.95
Erythropoiesis stimulating agent use 16 % 15 % 0.90
Studied by logistic regression. Mean values of baseline and data at 2 years were used
Data are given as percentage, mean (SD), or median [interquartile range]
eGFR estimated glomerular filtration rate, LDL low density lipoprotein, HDL high density lipoprotein, PTH
parathyroid hormone, FGF23 fibroblast growth factor 23, BMI body mass index
a Diabetes mellitus is defined as using blood glucose lowering medication or fasting glucose[7.0 mmol/l
b Cardiovascular disease is defined as myocardial infarction, stroke, or vascular intervention
c Using the MDRD equation re-expressed for standardized serum creatinine
d Measurement from the leg with the lower ankle brachial index was used
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the two groups. In multivariate analysis, older age, prior
cardiovascular disease, higher triglyceride levels, and higher
phosphate levels were independent determinants of a high
calcification score (Table 2).
Cardiovascular outcome
Median follow-up duration after the lateral lumbar X-ray was
2.4 years. A cardiovascular event occurred in 6 out of 141
patients with a low calcification score and in 20 out of 139
patients with a high calcification score (C4). The 26 cardio-
vascular events included: myocardial infarction (7 patients),
PCI (4 patients), stroke (3 patients), PTA (5 patients), bypass of
peripheral arteries (1 patient), aortic aneurysm (2 patients), and
cardiovascular mortality (4 patients).
Older age, renovascular cause of kidney disease, lower
eGFR, higher systolic blood pressure, higher protein cre-
atinine ratio, lower calcium, higher FGF23, lower hemo-
globin, lower serum albumin levels, and oral anticoagulant
drug use were associated with the composite cardiovascu-
lar outcome at univariate Cox regression analysis. The use
of aspirin was related to a lower cardiovascular event rate.
Moreover, a calcification score C4 was associated with
cardiovascular events (Table 3).
Multivariate Cox regression could not be performed
reliably, because of the low incidence of cardiovascular
events. Therefore, a propensity score matched sample was
used to evaluate whether a high calcification score added
prognostic value to known cardiovascular risk factors.
Sixty-eight matched pairs of patients with low and high
calcification score were included. Cardiovascular risk
factors were balanced between the two groups (Supple-
mentary Table 2). In the 68 patients with a low calcifica-
tion score, 5 had a cardiovascular event. In 12 out of 68
patients with a high calcification score a cardiovascular
event occurred. The hazard ratio (HR) for cardiovascular
events in the high calcification score group was 5.5 (95 %
confidence interval 1.2–24.8), p = 0.03. The Kaplan–
Meier curves are shown in Fig. 2.
Sensitivity analyses
The analyses evaluating absence versus presence of calci-
fication (calcification score 0 vs.[0) yielded similar results
to the analyses comparing patients with low and high cal-
cification score (Supplementary Tables 3 and 4, and Sup-
plementary Data 2). We did not observe major differences
in treatment changes after the X-ray between patients with
low vs. high calcification scores. The only differences we
observed were a slight increase in phosphate binder use in
patients with a high calcification score, and a small
decrease in beta blocker use in patients with a low calci-
fication score (data not shown).
Discussion
In this study, we showed that: (1) AAC was a common
occurrence in our population of non-dialysis CKD patients;
(2) older age, prior cardiovascular disease, higher triglyc-
eride levels, and higher phosphate levels were independent
determinants of a high calcification score; and, most
importantly, (3) AAC had prognostic value for cardiovas-
cular events in non-dialysis CKD patients.
Prevalence of AAC
AAC was common in our population of non-dialysis CKD
patients. Presence of AAC was found in 72 % of patients.
This is similar to results in other CKD populations [26, 27].
Decades ago, in fact, it was demonstrated that vascular cal-
cification is more extended and more severe in patients with
CKD than in age-matched healthy individuals [28]. Also,
vascular calcification increases gradually with progressing
CKD [29]. Using lateral lumbar X-rays, in dialysis patients an
AAC prevalence of up to 94 % has been described, with
duration of dialysis being independently associated with
severity of AAC [30]. For comparison, in the Framingham
Heart Study, a general population cohort, 67 % of 1030 men
(mean age 60.4 years), and 58 % of 1437 women (mean age
60.8 years) showed AAC on their X-ray [31]. Also in a
randomly selected sample of men from the region of Lyon,
France (STRAMBO cohort), in 780 men aged C60 years
(mean age 72 years) median Kauppila calcification score was
1 [IQR 0–4], and 41 % showed no aortic calcification [21]. In
a study of healthy living kidney donors, AAC was detected by
computed tomography (CT) in only 31 % [32].
Determinants of AAC
In our population, older age, prior cardiovascular disease,
higher triglyceride levels, and higher phosphate levels were
independent determinants of a high calcification score.
Table 2 Multivariate analysis, independent determinants of a high
calcification score
Characteristic OR 95 % CI p
Age/10 (years) 2.53 1.88–3.41 \0.001
Prior cardiovascular diseasea 2.42 1.30–4.50 0.01
Triglycerides/0.1 (mmol/l) 1.04 1.01–1.08 0.01
Phosphate/0.1 (mmol/l) 1.29 1.10–1.50 0.001
Studied by multivariate logistic regression
Nagelkerke R2 = 0.35–0.37
OR odds ratio, CI confidence interval
a Cardiovascular disease is defined as myocardial infarction, stroke,
or vascular intervention
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Age was the most important determinant of vascular
calcification. In CKD patients, dialysis patients, as well as
in the general population, a direct relationship between age
and AAC has been consistently observed [21, 26, 27, 30,
33, 34]. In addition, it has frequently been observed that
patients with (severe) AAC more often have a cardiovas-
cular disease history [26, 30, 33, 34]. Evidence on the role
of disturbances in bone and mineral metabolism in the
Table 3 Associations with
cardiovascular outcome in
univariate Cox regression
Characteristic HR 95 % CI p
Calcification score C4 3.86 1.55–9.62 0.004
Randomized to intervention group 0.53 0.24–1.14 0.11
Age/10 (years) 2.11 1.36–3.28 0.001
Male gender 1.05 0.46–2.41 0.92
Caucasian race 1.38 0.33–5.84 0.66
Renovascular cause of kidney disease 2.53 1.17–5.47 0.02
History of diabetes mellitusa 1.04 0.44–2.48 0.93
Prior cardiovascular diseaseb 1.50 0.68–3.32 0.31
eGFRc/5 (ml/min/1.73 m2) 0.83 0.69–0.99 0.04
Systolic blood pressure/10 (mmHg) 1.53 1.22–1.91 \0.001
Diastolic blood pressure/10 (mmHg) 1.04 0.70–1.55 0.83
Ankle brachial indexd/0.1 0.89 0.74–1.06 0.19
Ln protein creatinine ratio (Ln of mg/10 mmol) 1.21 1.00–1.46 0.049
Total cholesterol/0.1 (mmol/l) 1.02 0.98–1.07 0.38
LDL cholesterol/0.1 (mmol/l) 1.02 0.97–1.07 0.46
HDL cholesterol/0.1 (mmol/l) 0.96 0.86–1.07 0.42
Triglycerides/0.1 (mmol/l) 1.03 1.00–1.07 0.07
Calcium/0.1 (mmol/l) 0.60 0.41–0.88 0.01
Phosphate/0.1 (mmol/l) 1.06 0.88–1.27 0.56
Ln PTH (Ln of pmol/l) 1.45 0.74–2.87 0.28
Ln FGF23 (Ln of RU/ml) 1.89 1.26–2.82 0.002
Hemoglobin (mmol/l) 0.56 0.34–0.93 0.02
Serum albumin (g/l) 0.87 0.78–0.97 0.01
HbA1c (%) 1.30 0.83–2.04 0.25
BMI (kg/m2) 1.00 0.91–1.09 0.94
Smoking 1.09 0.44–2.74 0.85
Urinary sodium creatinine ratio/0.1 (mmol/mmol) 1.00 0.99–1.01 0.52
Physical activity guideline adherence 1.19 0.43–3.32 0.74
Aspirin use 0.40 0.18–0.88 0.02
Oral anticoagulant drug use 2.53 1.06–6.06 0.04
Statin use 0.82 0.25–2.75 0.75
Vitamin D use 1.46 0.68–3.15 0.34
Antihypertensive drug use 0.47 0.11–1.98 0.30
Calcium containing phosphate binder use 0.32 0.04–2.38 0.27
Sevelamer usee – – –
Erythropoiesis stimulating agent use 1.03 0.35–3.00 0.96
HR hazard ratio, CI confidence interval, eGFR estimated glomerular filtration rate, LDL low density
lipoprotein, HDL high density lipoprotein, PTH parathyroid hormone, FGF23 fibroblast growth factor 23,
BMI body mass index
a Diabetes mellitus is defined as using blood glucose lowering medication or fasting glucose[7.0 mmol/l
b Cardiovascular disease is defined as myocardial infarction, stroke, or vascular intervention
c Using the MDRD equation re-expressed for standardized serum creatinine
d Measurement from the leg with the lower ankle brachial index was used
e Adequate Cox regression was not possible, since there were no cardiovascular events in the patients who
used sevelamer
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development of AAC is not consistent. It is well known
that vascular calcification is not just a passive process of
calcium and phosphate deposition due to serum supersat-
uration. It is an active, complex, and dynamically regulated
process, resulting in phenotypical transformation of vas-
cular smooth muscle cells into osteoblast-like cells [35].
Although it seems obvious that, for instance, plasma
phosphate level plays an important role in this process [5,
36], it has not always been identified as a risk factor for
AAC in clinical studies [27, 30, 37]. Nevertheless, it is
likely that parameters of CKD-MBD interact at the patient
level to promote vascular calcification [11]. Recent data
point to concerns about excessive calcium intake, including
the use of calcium containing phosphate binders, with
regard to progression of cardiovascular calcification [38].
This will be one of the issues reconsidered in the KDIGO
CKD-MBD guideline update [39]. Furthermore, on the role
of triglyceride (or other lipid) levels, results are contra-
dictory [34, 37, 40]. It is well known that LDL cholesterol
plays a critical role in atherosclerosis. Besides, it is rec-
ognized that triglycerides, or rather the lipoproteins that
they are associated with, promote atherogenesis indepen-
dently of LDL cholesterol [41]. The majority of patients in
our study used a statin. Although statins have a triglyceride
lowering effect, their effect on LDL cholesterol is larger
[42]. Therefore, triglycerides may better reflect the lipid
profile prior to statin use that contributed to the develop-
ment of AAC. In addition, hypertriglyceridemia is in
general the most common dyslipidemia in CKD [43] and
might therefore be more strongly associated with AAC.
In studies using CT, eGFR proved an independent
determinant of AAC in non-dialysis CKD patients [12, 44].
Studies using plain X-rays have not always confirmed this
association [37, 40]. Also in our analyses, eGFR was not
associated with AAC. A factor that probably contributed to
this finding is that there was a difference in eGFR between
patients with and without a cardiovascular disease history:
eGFR was 39.4 and 35.1 ml/min/1.73 m2 in patients with
and without prior cardiovascular disease respectively
(p = 0.01). Since cardiovascular disease history was an
important determinant of AAC, it possibly masked the
effect of eGFR. We did not observe a relationship between
eGFR and other determinants of calcification.
Cardiovascular outcome
To the best of our knowledge, we are the first to show that
the Kauppila calcification score is associated with cardio-
vascular events in non-dialysis CKD patients. This indi-
cates that a lateral lumbar X-ray may provide information
that can aid in clinical decision making.
Imaging markers like AAC are often better outcome
predictors than serum markers, because they carry different
prognostic information. Cardiovascular calcification rep-
resents the cumulative result of prolonged exposure to
multiple risk factors, whereas serum markers only reflect
the risk at the time of measurement [45].
It was already known that the Kauppila calcification
score is independently related to cardiovascular morbidity
and mortality in the general population and in dialysis
patients [9, 10]. However, the association between vascular
calcification and cardiovascular events in non-dialysis
CKD patients has been scantly addressed. In non-dialysis
CKD patients it was known that both coronary artery cal-
cification [46] and AAC assessed by CT [12] are inde-
pendently related to cardiovascular events, that presence of
polyvascular calcification is associated with cardiovascular
mortality [47], and that AAC quantified by the Kauppila
calcification score correlates with coronary artery calcifi-
cation [48].
Strengths and limitations of our study
A lateral lumbar X-ray to assess severity of AAC is not as
sensitive as other modalities such as CT [45]. Therefore we
may have underestimated the severity of AAC in our
population. However, lateral lumbar X-rays also have
important advantages over CT: they are relatively inex-
pensive, involve low exposure to radiation, and are widely
available and easy to use in daily clinical practice.
Other investigators have shown good to excellent inter-
rater agreement on the Kauppila calcification score [17, 21,
26, 30, 34]. In these studies summary scores were used to
test inter-rater agreement. We used individual segment
scores, which are more accurate than summary scores. In
the other studies, the X-rays were often scored by experi-
enced radiologists. Although the two observers in our study
(MP and YK) were not radiologists, we also established a
very good inter-rater agreement. This is an important
Fig. 2 Incidence of the composite cardiovascular outcome in
propensity score matched patients. Stratified on matched pairs,
p = 0.03
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finding, since it implies that the semi-quantitative scoring
system, described by Kauppila et al. [17], is indeed a
simple imaging technique that can be readily used by
clinicians after minimal training.
Several laboratory parameters that are important in the
context of vascular calcification were not available, such as
serum vitamin D and fetuin-A levels. Moreover, AAC
could be the result of prolonged low-grade inflammation
[49]. In this context highly sensitive C-reactive protein
(hsCRP) is important. In MASTERPLAN, hsCRP values
were only available at baseline, and therefore we did not
include this parameter in our analysis. However, we did
study hsCRP at baseline. Median levels were 1.62 mg/l
[IQR 0.61–4.15] and 1.90 mg/l [IQR 0.93–5.13] in the low
and high calcification group, respectively (p = 0.17).
Unfortunately, data on dosage and duration of medica-
tion use were not available.
Another limitation of our study is that the patients
enrolled were participating in a clinical trial, and X-rays
were performed in a subgroup. In patients who participated
in the MASTERPLAN study, risk factor levels were
already quite well controlled at baseline [16]. Therefore,
the studied patients may not be representative of the CKD
population in general, compromising the study’s external
validity.
When compared to various other CKD cohorts, the
mortality rate in MASTERPLAN is among the lowest in
the world [50]. In this study, the cardiovascular event rate
was low during a limited follow-up. We used propensity
score matching instead of the traditional regression model
to circumvent problems of overfitting, and were able to
demonstrate the prognostic value of AAC by lateral lumbar
X-ray in non-dialysis CKD patients.
Conclusion
Our study supports the recommendation in the KDIGO
guideline that assessment of AAC in CKD patients can
identify patients at higher cardiovascular risk and may
provide important information for personalized treatment.
Whether this approach will ultimately translate into better
outcomes, however, remains to be answered.
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